XXA1-BH3

General Information


DRACP ID  DRACP03026

Peptide Name   XXA1-BH3

Sequence  RPEIWYAQGLKRFGDEFNAYYAR

Sequence Length  23

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Induce apoptosis Bcl-xL inhibitors BH3 peptides and mimetics



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MDA-MB-231 (Bc1-xL dependent) Breast adenocarcinoma Carcinoma EC50=50 ± 16 nM Not available Not available 1
OCI-Ly1 (Bcl-2 dependent) Diffuse large B-cell lymphoma Lymphoma EC50=228 ± 56 nM Not available Not available 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Bcl-xL

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP03026

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C133H188N36O35

Absent amino acids  CHMSTV

Common amino acids  ARY

Mass  324376

Pl  9.05

Basic residues  4

Acidic residues  3

Hydrophobic residues  8

Net charge  1

Boman Index  -5981

Hydrophobicity  -99.13

Aliphatic Index  46.96

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  9970

Absorbance 280nm  453.18

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25451027

Title  Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL

Doi 10.1016/j.jmb.2014.09.030

Year  2015

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.